Q2 FY2026 EarningsQ2 FY26 results missed consensus on the top line, with revenue of $29.8M vs. $30.5M expected (-2.4%), driven by weakness in the ingredient business. GAAP EPS of $0.01 beat the $0.008 mean estimate, supported by a 64.8% gross margin which exceeded the 64.6% consensus. While operating cash flow of $1.6M YTD fell short of the $2.0M projected for the quarter, the launch of the Niagen Plus telehealth platform and pharmaceutical program marks a strategic shift toward a multi-asset model.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Niagen Bioscience(NAGE) the Revenue is 29.79 M (-4.28%), Miss estimate;the EBIT is 700 K (-78.02%), Miss estimate;the EPS is 0.01 (-75%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.03B4.28%
0.03B1.88%
-0.00B2.40%
EBITMiss expectations
0.00B78.02%
0.00B67.59%
-0.00B10.43%
EPSExceed expectations
0.0175.00%
0.008379.18%
+0.00174.18%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf